In June 2017, the FDA issued a new draft guidance document on 21 CFR Part 11 for public comment. The guidance document covers five areas, including a discussion on mobile technology in clinical research.
Even though the guidance is still in draft form, the information it contains is so critical to the industry that we decided to share the FDA’s current thinking on the topic with you.
To learn how 21 CFR Part 11 applies to mobile technology in clinical trials, download our new guide.
Complete the form below to download the guide.